Unloxcyt Approved for Treating Squamous Cell Skin Cancer
The U.S. Food and Drug Administration (FDA) has announced the approval of a new drug developed by Checkpoint Therapeutics for the treatment of a type of cancer affecting the outer layer of the skin.
The medication, cosibelimab-ipdl, which will be marketed under the brand name Unloxcyt, has been approved for squamous cell skin cancer. It can be used in cases where the cancer has advanced locally or has spread to other parts of the body.
Unloxcyt belongs to a class of drugs known as PD-L1 antibodies. These drugs work by binding to a protein called programmed death-ligand 1 (PD-L1), helping the immune system destroy cancer cells.
The FDA’s approval was based on results from a study involving 109 patients. In this study, Unloxcyt achieved an overall response rate of 47% in patients with metastatic cancer and 48% in those with locally advanced forms of the disease.
End of Message
Feel free to share this content with attribution to The World of Health and Medicine.
